Genzyme Corp has posted a strong set of results for the fourth quarter of 2007, with growth being driven once again by Cerezyme, Fabrazyme and Renagel.

Net income was $78.9 million, or $0.29 per share, compared with a loss of $268.2 million, or $1.02 per share in the like, year-earlier period when the company took a charge related to acquisitions. Revenues rose 21% to $1.04 billion, driven by sales of Gaucher disease treatment Cerezyme (imiglucerase), up 15% to $301 million and Fabry disease drug Fabrazyme (agalsidase beta), which added $114 million (+18%) to the coffers.

Genzyme also made special mention of Myozyme (alglucosidase alfa), its new treatment for Pompe disease, which brought in $62 million in the quarter, up 106.6%, and another strong contribution to turnover came from Renagel (sevelamer HCl), which treats end-stage kidney disease and was up 23% to $167 million.

The company said that it expects revenues to reach $4.5-$4.7 billion in 2008 as part of its goal to increase its top line at a rate of 16%-17% percent over the five-year period from 2006-2011. Earnings excluding items should reached $4 per share.